Improve the quality and efficiency of R&D results by making stratified medicine a reality
The
World Companion Diagnostics Summit 2010, Boston, November 30th - December 3rd, will be addressing exactly these most crucial challenges. Developed in collaboration with the companion diagnostic pioneers from Roche, Genentech, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Amgen, Abbott, Qiagen and Dako, the meeting has evolved from the urgent need for those committed to personalized medicine to come together and share expertise that will underpin the path for making companion diagnostics a reality.
What`s on the agenda at World Companion Diagnostics Summit 2010?
- Identifying critical biomarkers for companion diagnostic development - generating robust biomarker hypotheses, deciding when to commit to a biomarker program, determining which biomarkers have most clinical relevance
- Achieving clinical validation of Companion Diagnostics - ensuring biomarker assay is developed before reaching the clinic, improving clinical trial design with companion diagnostics, achieving validation of both drug and diagnostic together,
- Addressing the Commercial and regulatory viability of companion diagnostics - how to achieve reimbursement, anticipating regulatory hurdles, assessing the value of your companion diagnostic throughout development
- Finding the optimal partnering solutions to successfully develop a companion diagnostic - who is the best partner? What is the selection criteria? What is the best deal structure? When should you partner? Ensuring compatibility of business models
- Making companion diagnostics a clinical reality - ensuring healthcare providers will use your diagnostic, aligning drug and diagnostic development timelines for simultaneous release to market, strategies for co-promotion of a diagnostic and drug, developing a transferable assay compatible with the clinical routine
Visitors profilePharmaceutical, Biotechnology, Diagnostics
